Skip to content

    Recently Viewed


      Cilag Gmbh International Completes Acquisition Of Over-The-Counter Brands Of J B Chemicals & Pharmaceuticals Limited

      Share Article
      share to

      Zug, Switzerland, July 14, 2011 – Cilag GmbH International today announced the completion of the acquisition of the over-the-counter (OTC) brands of J B Chemicals & Pharmaceuticals Limited for the equivalent of approximately U.S. $245 million in cash. The brands included in the acquisition are RINZA®, Russia’s leading multi-symptom cough and cold brand, and DOKTOR MOM®, Russia’s number two selling cough brand, as well as several other brands. Johnson & Johnson LLC and its affiliates will market these products in Russia, the world’s eighth largest OTC market, and in the Commonwealth of Independent States and other countries. Cilag GmbH International and Johnson & Johnson LLC are wholly-owned subsidiaries of Johnson & Johnson.


      (This press release contains “forward-looking statements” as defined in the Private Securities Litigation Reform Act of 1995. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or unknown risks or uncertainties materialize, actual results could vary materially from the expectations and projections of Cilag GmbH International, Johnson & Johnson LLC and/or Johnson & Johnson. Risks and uncertainties include, but are not limited to, general industry conditions and competition; economic factors, such as interest rate and currency exchange rate fluctuations; technological advances and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approvals; domestic and foreign health care reforms and governmental laws and regulations; trends toward health care cost containment; and increased scrutiny of the healthcare industry by government agencies. In addition, there will be risks and uncertainties related to the ability of Cilag GmbH International and Johnson & Johnson LLC to successfully integrate the acquired products of J B Chemicals & Pharmaceuticals Limited, as well as the ability to ensure continued performance or market growth of the acquired products of J B Chemicals & Pharmaceuticals Limited. A further list and description of these risks, uncertainties and other factors can be found in Exhibit 99 of Johnson & Johnson’s Annual Report on Form 10-K for the fiscal year ended January 2, 2011. Copies of this Form 10-K, as well as subsequent filings, are available online at, or on request from Johnson & Johnson. Cilag GmbH International, Johnson & Johnson LLC, and Johnson & Johnson do not undertake to update any forward-looking statements as a result of new information or future events or developments.)

      Media Contacts
      Marc Boston
      215-273-7649 (office)
      215-429-7034 (mobile)

      Bonnie Jacobs
      215-273-8994 (office)
      856-912-9965 (mobile)

      Investor Relations Contacts
      Johnson & Johnson
      Ellen Sipos
      732 524-3709 (office)

      Lesley Fishman
      732 524-3922 (office)

      You are now leaving and going to a site with a different privacy policy. Please click below to continue to that site.